Journal
AMERICAN JOURNAL OF INFECTIOUS DISEASES
Volume 2, Issue 3, Pages 159-166Publisher
SCIENCE PUBLICATIONS
DOI: 10.3844/ajidsp.2006.159.166
Keywords
HIV; glucose; lipids; protease inhibitor; antiretroviral
Categories
Funding
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL074814] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057508, R01DK066999] Funding Source: NIH RePORTER
- NHLBI NIH HHS [R01 HL074814-04, R01 HL074814] Funding Source: Medline
- NIDDK NIH HHS [R01 DK066999, R01 DK066999-08, R01 DK066999-03, R01 DK057508-03, R01 DK066999-05, R01 DK066999-04, R01 DK066999-02, R01 DK066999-07, R01 DK066999-01, R01 DK057508-01, R01 DK066999-06, R01 DK057508] Funding Source: Medline
Ask authors/readers for more resources
The use of protease inhibitors and non-nucleoside reverse transcriptase inhibitors for the treatment of HIV infection and AIDS has been associated with multiple abnormalities in glucose and lipid metabolism. Specifically, these abnormalities include insulin resistance, increased triglycerides and increased LDL cholesterol levels. The metabolic disturbances are due to a combination of factors, including the direct effect of medications, restoration to health and HIV disease, as well as individual genetic predisposition. Of the available anti-retroviral medications, indinavir has been associated with causing the most insulin resistance and ritonavir with causing the most hypertriglyceridemia.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available